Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02338115 · ClinicalTrials.gov registry record
Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients
A clinical trial, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- 60
- Enrollment target
NCT02338115: Completed study, sponsored by University of Michigan Rogel Cancer Center.
NCT02338115 is a clinical trial that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02338115 has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
The purpose of this prospective observational study is to understand the relationship between paclitaxel exposure and development of peripheral neuropathy during treatment.
Primary Outcome
Increase in sensory scale of PRO measure of 5 points or more
Interventions
- DRUG Paclitaxel 80mg/m2 weekly x 12 weeks
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2014-05 |
| Est. Completion | 2016-12-20 |
What the finished NCT02338115 record still lists
NCT02338115 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Paclitaxel 80mg/m2 weekly x 12 weeks is the first listed.
NCT02338115 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02338115 about?
NCT02338115 is a clinical study titled "Defining an Exposure Target for Weekly Paclitaxel Infusion in Breast Cancer Patients". The purpose of this prospective observational study is to understand the relationship between paclitaxel exposure and development of peripheral neuropathy during treatment.
What is the current status of trial NCT02338115?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2014-05. Estimated completion is 2016-12-20.
What interventions are being tested in trial NCT02338115?
The interventions under investigation include: Paclitaxel 80mg/m2 weekly x 12 weeks (DRUG).
Who is sponsoring clinical trial NCT02338115?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia